Lyell Immunopharma (LYEL) Leases: 2020-2025
Historic Leases for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $19.9 million.
- Lyell Immunopharma's Leases fell 45.69% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 45.69%. This contributed to the annual value of $24.7 million for FY2024, which is 37.63% down from last year.
- Lyell Immunopharma's Leases amounted to $19.9 million in Q3 2025, which was down 4.96% from $21.0 million recorded in Q2 2025.
- In the past 5 years, Lyell Immunopharma's Leases registered a high of $48.4 million during Q2 2021, and its lowest value of $19.9 million during Q3 2025.
- Moreover, its 3-year median value for Leases was $37.7 million (2024), whereas its average is $33.3 million.
- Data for Lyell Immunopharma's Leases shows a maximum YoY crashed of 45.69% (in 2025) over the last 5 years.
- Lyell Immunopharma's Leases (Quarterly) stood at $46.5 million in 2021, then dropped by 7.09% to $43.2 million in 2022, then declined by 8.28% to $39.7 million in 2023, then tumbled by 37.63% to $24.7 million in 2024, then crashed by 45.69% to $19.9 million in 2025.
- Its Leases stands at $19.9 million for Q3 2025, versus $21.0 million for Q2 2025 and $23.6 million for Q1 2025.